Roche Says Experimental MS Pill Cuts Relapses 55% in Late-Stage Trials
Roche said late-stage trial data showed its experimental fenebrutinib reduced markers of chronic brain inflammation and delivered broader disease control than comparator treatments in patients with relapsing and primary progressive multiple sclerosis.
Roche (ROG.S) said on Wednesday that late-stage trial results showed its experimental drug fenebrutinib reduced markers of chronic brain inflammation and provided broader disease control than comparator treatments in patients with relapsing and primary progressive multiple sclerosis (MS).